


Amendments to the Claims

This listing of claims will replace all prior versions and listings of claims in the application:

1. (presently amended) The present invention relates to a variety of compounds which are useful according to the present invention. These compounds are represented by the following Formula A:



wherein **R**, **R**¹ and **R**² are independently chosen from hydrogen, C₁₋₄alkyl;
R³ is selected from hydrogen, C₁₋₄alkyl, or **R**² and **R**³ can complete a pyrrolidine or piperidine ring, which can be substituted with C₁₋₄alkyl;
R⁴ is hydrogen, halogen, C₁₋₄alkyl;
R⁵ and **R**⁶ are independently chosen from hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfoxide, nitrile, C₁₋₆alkyl substituted with halogen;
R⁷ is chosen from

C=OR⁹;

S(O)_mR¹⁰;

NR¹-(C=O)-R¹¹;

C₁₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, OC(=O)C₁₋₈, CO₂H,

CO₂C₁₋₆alkyl, C(=O)NR¹²R¹³, S(O)_mNR¹²R¹³, NR¹⁴R¹⁵, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4

heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl, phenyl or pyridinyl; or **R**⁷ can be chosen from a heterocyclic ring selected from oxazol-2-yl; 4,5-dihydro-oxazol-2-yl; σ -benzoxazol-2-yl; 5,6-dihydro-[1,3]oxazin-2-yl; thiazol-2-yl; 4,5-dihydro-thiazol-2-yl; σ -benzothiazol-2-yl; imidazol-2-yl; imidazolidin-2-yl; [1,2,4]oxadiazol-5-yl; [1,2,4]oxadiazol-3-yl; [1,2,4]thiadiazol-5-yl; or [1,2,4]thiadiazol-3-yl, each of which can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, pyridinyl, or C₁₋₆alkyl substituted with phenyl or pyridinyl;

but **R**⁷ cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

R⁸ is selected from C₁₋₆alkyl, phenyl which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, NR¹(C=O)C₁₋₆alkyl, or halogen;

R⁹ is chosen from hydroxyl; C₁₋₆alkoxy; C₁₋₆alkoxy substituted with phenyl or pyridinyl which can be substituted with C₁₋₄alkoxy or halogen; NR¹⁶R¹⁷; C₁₋₆alkyl; or C₁₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, NR¹²R¹³, CO₂H, CO₂C₁₋₆alkyl, S(O)_mNR¹²R¹³, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazolyl, morpholinyl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl;

R¹⁰ is chosen from NR¹²R¹³; C₁₋₆alkyl; CH₂phenyl or CH₂pyridinyl which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or haloC₁₋₄alkyl; or C₂₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, NR¹²R¹³, CO₂H, CO₂C₁₋₆alkyl, phenyl, pyridinyl or imidazolyl which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl;

R¹¹ is NH₂; NR¹R²; C₁₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, CO₂H, CO₂C₁₋₆alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which

can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl;

R¹² and R¹³ are independently selected from hydrogen; C₁₋₆alkyl; CH₂Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or haloC₁₋₄alkyl; C₂₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, CO₂H, CO₂C₁₋₆alkyl, NR¹COC₁₋₆alkyl, or halogen; or R¹², R¹³, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C₁₋₄alkyl or C₁₋₄alkyl substituted with hydroxy, C₁₋₄alkoxy or halogen;

R¹⁴ and R¹⁵ are independently selected from hydrogen, C₁₋₆alkyl, hydroxyl, C₁₋₆alkoxy, (C=O)-R¹¹, S(O)_mR⁸, phenyl or pyridinyl which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or haloC₁₋₄alkyl; or R¹⁴, R¹⁵ and the nitrogen atom to which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with C₁₋₆alkyl, phenyl, or pyridinyl;

R¹⁶ and R¹⁷ are independently selected from hydrogen; C₁₋₆alkyl; hydroxyl; C₁₋₆alkoxy; CH₂Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or haloC₁₋₄alkyl; C₂₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, halogen, NR¹(C=O)C₁₋₆alkyl, or a phenyl or a heterocyclic ring selected from a pyrrole, such as pyrrolidin-2-yl; an imidazole such as imidazo-2-yl or imidazo-4-yl; a morpholine such as morpholin-3-yl; a piperidine such as piperidin-4-yl; oxazolyl; isoxazolyl; thiazolyl; tetrazolyl; pyridinyl; each of which can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl, phenylC₁₋₄alkyl, oxo (=O); or R¹⁶, R¹⁷, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine

1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C₁₋₄alkyl or C₁₋₄alkyl substituted with hydroxy, oxo (=O), C₁₋₄alkoxy, or phenyl;

m is 0 – 2;

A is N or CH; and

X and **Y** are either N or C, wherein **X** and **Y** cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

2. (presently amended) The method of claim 1, wherein for the compound of Formula A:

R, **R**¹ and **R**² are independently chosen from hydrogen, C₁₋₄alkyl;

R³ is selected from hydrogen, C₁₋₄alkyl, or **R**² and **R**³ can complete a pyrrolidine or piperidine ring, which can be substituted with C₁₋₄alkyl;

R⁴ is hydrogen, C₁₋₄alkyl;

R⁵ and **R**⁶ are independently chosen from hydrogen, halogen, C₁₋₆alkyl, C₁₋₆alkylthio, C₁₋₆alkylsulfonyl, C₁₋₆alkylsulfoxide, nitrile, C₁₋₆alkyl substituted with halogen;

R⁷ is chosen from

C=OR⁹;

C₁₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, OC(=O)C₁₋₈, CO₂H,

CO₂C₁₋₆alkyl, C(=O)NR¹²R¹³, S(O)_mNR¹²R¹³, NR¹⁴R¹⁵, phenyl or a saturated

or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4

heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl, phenyl or pyridinyl; or

R⁷ can be chosen from a heterocyclic ring selected from oxazol-2-yl; 4,5-dihydro-oxazol-2-yl; benzoxazol-2-yl; 5,6-dihydro-[1,3]oxazin-2-yl; thiazol-2-yl; 4,5-dihydro-thiazol-2-yl; benzothiazol-2-yl; imidazol-2-yl; imidazolidin-2-yl;

[1,2,4]oxadiazol-5-yl; [1,2,4]oxadiazol-3-yl; [1,2,4]thiadiazol-5-yl; or

[1,2,4]thiadiazol-3-yl, each of which can be unsubstituted or substituted with

C₁₋₆alkyl, C₁₋₆alkoxy, phenyl, pyridinyl, or C₁₋₆alkyl substituted with phenyl or pyridinyl;

but **R**⁷ cannot be hydrogen, lower alkyl, hydroxyl, lower alkoxy, amino, mono- or di-loweralkyl amino, lower alkanoylamino, or halogen;

R⁸ is selected from C₁₋₆alkyl, phenyl which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, NR¹(C=O)C₁₋₆alkyl, or halogen;

R⁹ is chosen from hydroxyl; C₁₋₆alkoxy; C₁₋₆alkoxy substituted with phenyl or pyridinyl which can be substituted with C₁₋₄alkoxy or halogen; NR¹⁶R¹⁷; C₁₋₆alkyl; or C₁₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, NR¹²R¹³, CO₂H, CO₂C₁₋₆alkyl, S(O)_mNR¹²R¹³, halogen, or phenyl or a heterocyclic ring selected from pyrrolidinyl, imidazolyl, morpholinyl, oxazolyl, isoxazolyl, thiazolyl, or tetrazolyl, or pyridinyl which can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl;

R¹¹ is NH₂; NR¹R²; C₁₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, CO₂H, CO₂C₁₋₆alkyl, phenyl or a saturated or unsaturated 5 or 6-membered heterocyclic ring which can contain 1-4 heteroatoms selected from N, O, or S and can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl;

R¹² and **R**¹³ are independently selected from hydrogen; C₁₋₆alkyl; CH₂Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or haloC₁₋₄alkyl; C₂₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, CO₂H, CO₂C₁₋₆alkyl, NR¹COC₁₋₆alkyl, or halogen; or R¹², R¹³, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C₁₋₄alkyl or C₁₋₄alkyl substituted with hydroxy, C₁₋₄alkoxy or halogen;

R¹⁴ and **R**¹⁵ are independently selected from hydrogen, C₁₋₆alkyl, hydroxyl, C₁₋₆alkoxy, (C=O)-R¹¹, S(O)_mR⁸, phenyl or pyridinyl which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or haloC₁₋₄alkyl; or R¹⁴, R¹⁵ and the nitrogen atom to

which they are attached can form a heterocyclic ring selected from pyrrolidine, piperazine, or piperidine, which can be substituted with C₁₋₆alkyl, phenyl, or pyridinyl;

R¹⁶ and **R¹⁷** are independently selected from hydrogen; C₁₋₆alkyl; hydroxyl; C₁₋₆alkoxy; CH₂Z, where Z is selected from phenyl, pyridinyl, furanyl, thiophenyl, pyrimidinyl, pyrazinyl, or pyridazinyl, and which can be substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, or haloC₁₋₄alkyl; C₂₋₆alkyl substituted with hydroxyl, C₁₋₆alkoxy, halogen, NR¹(C=O)C₁₋₆alkyl, or a phenyl or a heterocyclic ring selected from a pyrrole, such as pyrrolidin-2-yl; ~~an imidazole such as imidazo-2-yl or imidazo-4-yl;~~ a morpholine such as morpholin-3-yl; a piperidine such as piperidin-4-yl; oxazolyl; isoxazolyl; thiazolyl; tetrazolyl; pyridinyl; each of which can be unsubstituted or substituted with C₁₋₆alkyl, C₁₋₆alkoxy, halogen, haloC₁₋₄alkyl, phenylC₁₋₄alkyl, oxo (=O); or **R¹⁶**, **R¹⁷**, and the intervening nitrogen atom can form a heterocyclic ring selected from morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine 1,1-dioxide, azetidine, pyrrolidine, piperidine, piperazine, unsubstituted or substituted with C₁₋₄alkyl or C₁₋₄alkyl substituted with hydroxy, oxo (=O), C₁₋₄alkoxy, or phenyl;

m is 0 – 2;

A is N; and

X and **Y** are either N or C, wherein **X** and **Y** cannot be the same; and the dashed bonds denote a suitably appointed single and double bond.

3. (original) The method of claim 2, wherein the compound of Formula A is:

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid amide;

1-((S)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid methyl amide fumarate;

1-((*S*)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (1-hydroxy-cyclopropylmethyl)-amide; or

1-((*S*)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.

4. (original) The method of claim 3, wherein the compound of Formula A is 1-((*S*)-2-aminopropyl)-1*H*-furo[2,3-*g*]indazole-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide.

5 – 9. (Cancelled).